Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

A bipartisan, bicameral group of lawmakers is calling on the Federal Trade Commission (FTC) to vote in favor of releasing an interim staff report on pharmacy benefit managers (PBM). Sens.

The Federal Trade Commission (FTC) released a 60-page report Tuesday targeting the three biggest pharmacy benefit managers (PBMs), claiming the companies hiked the prices of specialty drugs by ...

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

The FTC's long-awaited report published in July was a difficult read for the PBM industry, concluding that the six largest companies in the US market operate a concentrated market structure that ...